Our Pipeline

Best-In-Class Cancer Therapuetics

Anticipated Data Readouts and Partnerships Provide Multiple Potential 2023 Value Drivers for Sutro

Six Product Candidates in Clinical Development are Enabled by Sutro’s Platform


Sutro Biopharma is a clinical stage company working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies, and cytokine-based therapeutics targeting immuno-oncology and autoimmune pathways.

Our Pipeline of Product Candidates and Programs, all based on our proprietary XpressCF® and XpressCF+® platforms, are summarized in the chart below: